Tech Company Financing Transactions
Onward Therapeutics Funding Round
Onward Therapeutics, based in Taipei, scored $28 million from CDIB Capital Group, Hercules Capital and Taiwania Capital.
Transaction Overview
Company Name
Announced On
11/18/2026
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to advance its clinical programs, manufacture clinical supplies, and support early-stage R&D, while expanding its team and initiating clinical trials in Taiwan.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
No. 60, Songjiang Road, Zhongshan District 2F
Taipei, 104090
Taiwan
Taipei, 104090
Taiwan
Phone
Undisclosed
Website
Email Address
Overview
We are a clinical-stage oncology company focused on identifying innovative technologies and advancing truly breakthrough medicines for the treatment of cancer. Led by an experienced team in translational science and drug development, we acquire licenses for high potential development candidates, we invest in partners with transformative technology platforms, and we build our own internal programs.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/18/2026: Sequel.io venture capital transaction
Next: 11/19/2026: StepSecurity venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








